Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Simon G. Anderson, David C. Hutchings, Mark Woodward, Kazem Rahimi, Martin K. Rutter, Mike Kirby, Geoff Hackett, Andrew W. Trafford, Adrian H. Heald

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality'. Together they form a unique fingerprint.

Medicine & Life Sciences